Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 201

Drug Profile

IMM 201

Alternative Names: DAR 901; Heat-killed Mycobacterium vaccae strain NCTC 11659; IMM-201; SRL 172

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silence Therapeutics
  • Developer Aeras; Geisel School of Medicine; Immodulon Therapeutics; Tokyo Medical and Dental University; University of Colorado at Boulder
  • Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Preclinical Post-traumatic stress disorders
  • Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in USA (Intradermal, Injection)
  • 21 Jul 2017 Preclinical trials in Post-traumatic stress disorder in USA (Injection) (Immodulon pipeline, July 2017)
  • 21 Jul 2017 Pharmacodynamics data from a preclinical trial in Post-traumatic stress disorder released by Immodulon Therapeutics (Immodulon pipeline, July 2017)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top